RU2008103608A - Выявление антигена-мишени вне зависимости от присутствия или отсутствия соответствующего терапевтического антитела - Google Patents

Выявление антигена-мишени вне зависимости от присутствия или отсутствия соответствующего терапевтического антитела Download PDF

Info

Publication number
RU2008103608A
RU2008103608A RU2008103608/15A RU2008103608A RU2008103608A RU 2008103608 A RU2008103608 A RU 2008103608A RU 2008103608/15 A RU2008103608/15 A RU 2008103608/15A RU 2008103608 A RU2008103608 A RU 2008103608A RU 2008103608 A RU2008103608 A RU 2008103608A
Authority
RU
Russia
Prior art keywords
therapeutic antibody
target antigen
sample
antibody
complex
Prior art date
Application number
RU2008103608/15A
Other languages
English (en)
Russian (ru)
Inventor
Хельмут ЛЕНЦ (DE)
Хельмут ЛЕНЦ
Вернер ШОЙЕР (DE)
Вернер ШОЙЕР
Мартина ТИР (DE)
Мартина ТИР
Original Assignee
Ф.Хоффманн-Ля Рош Аг (Ch)
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг (Ch), Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг (Ch)
Publication of RU2008103608A publication Critical patent/RU2008103608A/ru

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
RU2008103608/15A 2005-07-06 2006-07-05 Выявление антигена-мишени вне зависимости от присутствия или отсутствия соответствующего терапевтического антитела RU2008103608A (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05014618 2005-07-06
EP05014618.2 2005-07-06
EP06004447.6 2006-03-06
EP06004447 2006-03-06

Publications (1)

Publication Number Publication Date
RU2008103608A true RU2008103608A (ru) 2009-08-20

Family

ID=36922121

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008103608/15A RU2008103608A (ru) 2005-07-06 2006-07-05 Выявление антигена-мишени вне зависимости от присутствия или отсутствия соответствующего терапевтического антитела

Country Status (19)

Country Link
US (1) US20070009976A1 (enrdf_load_stackoverflow)
EP (2) EP2194380A3 (enrdf_load_stackoverflow)
JP (1) JP2008545145A (enrdf_load_stackoverflow)
KR (1) KR20080016939A (enrdf_load_stackoverflow)
AR (1) AR053948A1 (enrdf_load_stackoverflow)
AU (1) AU2006265275A1 (enrdf_load_stackoverflow)
BR (1) BRPI0612591A2 (enrdf_load_stackoverflow)
CA (1) CA2613187A1 (enrdf_load_stackoverflow)
CR (1) CR9635A (enrdf_load_stackoverflow)
EC (1) ECSP088081A (enrdf_load_stackoverflow)
IL (1) IL188317A0 (enrdf_load_stackoverflow)
MA (1) MA29730B1 (enrdf_load_stackoverflow)
MX (1) MX2008000277A (enrdf_load_stackoverflow)
MY (1) MY157955A (enrdf_load_stackoverflow)
NO (1) NO20076662L (enrdf_load_stackoverflow)
NZ (1) NZ564471A (enrdf_load_stackoverflow)
RU (1) RU2008103608A (enrdf_load_stackoverflow)
TW (1) TWI312864B (enrdf_load_stackoverflow)
WO (1) WO2007003420A1 (enrdf_load_stackoverflow)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0111355A (pt) * 2000-05-19 2003-04-29 Genentech Inc Método para o aumento da probabilidade de eficácia de um tratamento contra o câncer com antagonistas de erbb, método para o aumento da probabilidade de eficácia de um anticorpo anti-her2 no tratamento de câncer, embalagem farmacêutica, método para a identificação de um paciente disposto a responder favoravelmente a um antagonista de erbb para o tratamento de câncer e usos
KR20180091967A (ko) 2004-07-22 2018-08-16 제넨테크, 인크. Her2 항체 조성물
WO2006039486A2 (en) 2004-10-01 2006-04-13 The Board Of Trustees Of The Leland Stanford Junior University Imaging arrangements and methods therefor
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2006216732C1 (en) 2005-02-23 2017-07-20 Genentech, Inc. Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US8358354B2 (en) 2009-01-26 2013-01-22 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical abberations
WO2007092581A2 (en) 2006-02-07 2007-08-16 The Board Of Trustees Of The Leland Stanford Junior University Correction of optical aberrations
KR20150039212A (ko) 2007-03-02 2015-04-09 제넨테크, 인크. 낮은 her3 발현을 기초로 한 her 이량체화 억제제에 대한 반응 예측
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
SI4241849T1 (sl) 2011-10-14 2025-01-31 F. Hoffmann-La Roche Ag Načini uporabe in proizvodni izdelek, vključno s pertuzumabom - zaviralcem dimerizacije receptorja HER2
KR101327542B1 (ko) * 2012-03-15 2013-11-08 광주과학기술원 양자점 기반의 경쟁 면역분석법 및 다중 유세포 분석법을 이용한 시료 중 오염물질의 검출 방법
AU2012232949B2 (en) * 2012-09-28 2014-07-03 Willowtree Holdings Pty Ltd Temporary bulkhead
NZ751877A (en) 2013-04-16 2020-04-24 Genentech Inc Pertuzumab variants and evaluation thereof
JP2017513901A (ja) 2014-04-25 2017-06-01 ジェネンテック, インコーポレイテッド トラスツズマブ−mcc−dm1及びペルツズマブにより早期の乳癌を処置する方法
JP6822980B2 (ja) 2015-05-30 2021-01-27 ジェネンテック, インコーポレイテッド Her2陽性転移性乳癌の治療方法
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
JP6914336B2 (ja) 2016-12-28 2021-08-04 ジェネンテック, インコーポレイテッド 進行したher2発現がんの治療
KR20200113292A (ko) 2017-01-17 2020-10-06 제넨테크, 인크. 피하 her2 항체 제형
IL289297B2 (en) 2017-03-02 2023-09-01 Hoffmann La Roche Adjuvant treatment for her2-positive breast cancer
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain
AU2020456731A1 (en) 2020-06-29 2023-01-05 F. Hoffmann-La Roche Ag Pertuzumab plus trastuzumab fixed dose combination

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
WO1993021319A1 (en) 1992-04-08 1993-10-28 Cetus Oncology Corporation HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES
EP0931147A1 (en) 1996-10-18 1999-07-28 Genentech, Inc. ANTI-ErbB2 ANTIBODIES
EP1438583B1 (en) * 2001-09-20 2009-09-16 Board of Regents, The University of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
HUP0600340A3 (en) * 2002-07-15 2011-06-28 Genentech Inc Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies

Also Published As

Publication number Publication date
JP2008545145A (ja) 2008-12-11
MX2008000277A (es) 2008-03-24
AR053948A1 (es) 2007-05-23
MY157955A (en) 2016-08-30
AU2006265275A1 (en) 2007-01-11
TWI312864B (en) 2009-08-01
EP1902315A1 (en) 2008-03-26
TW200741203A (en) 2007-11-01
US20070009976A1 (en) 2007-01-11
WO2007003420A1 (en) 2007-01-11
NZ564471A (en) 2010-04-30
BRPI0612591A2 (pt) 2010-11-23
ECSP088081A (es) 2008-02-20
CR9635A (es) 2008-02-20
MA29730B1 (fr) 2008-09-01
EP2194380A3 (en) 2010-07-14
IL188317A0 (en) 2008-04-13
NO20076662L (no) 2008-04-03
KR20080016939A (ko) 2008-02-22
CA2613187A1 (en) 2007-01-11
EP2194380A2 (en) 2010-06-09

Similar Documents

Publication Publication Date Title
RU2008103608A (ru) Выявление антигена-мишени вне зависимости от присутствия или отсутствия соответствующего терапевтического антитела
JP2008545145A5 (enrdf_load_stackoverflow)
CY1112631T1 (el) ΜΕΘΟΔΟΙ ΤΑΥΤΟΠΟΙΗΣΗΣ ΟΓΚΩΝ ΠΟΥ ΑΠΟΚΡΙΝΟΝΤΑΙ ΣΕ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΕrbB2
CA2749846A1 (en) Methods of determining patient response by measurement of her-3
CN110383068A (zh) 评估患者样品中uch-l1状态的改进方法
DE50306067D1 (de) Nachweis von tsh-rezeptor-autoantikörpern mit affinitätsgereinigten antikörpern
DK1668368T3 (da) Detektion af histon-modifikation i cellefrie nukleosomer
WO2018175942A1 (en) Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
WO2010038974A3 (ko) 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트
FR2933773B1 (fr) Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
RU2014103054A (ru) Применение антитела i-3859 для выявления и диагностики рака
JP4608432B2 (ja) 腫瘍マーカーとしてのn▲1▼,n▲12▼−ジアセチルスペルミン
US20150198598A1 (en) Kit for diagnosing malignant melanoma
FI3356826T3 (fi) Gdf-15 melanooman diagnostisena markkerina
US11242408B2 (en) Monoclonal antibody specific for gamma-glutamyl-l-epsilon-lysine for the monitoring of apoptosis
ATE532796T1 (de) Immunassays zur spezifischen bestimmung von scca- isoformen
KR20240139074A (ko) 샘플에서 유비퀴틴 카르복시-말단 히드롤라제 l1 및/또는 신경교 섬유성 산성 단백질의 존재를 검출하거나 또는 그의 양을 측정하기 위한 측면 유동 방법, 검정 및 기기
EP3602069A1 (en) Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
AU2022339759A1 (en) Methods and systems of diagnosing brain injury
ATE493662T1 (de) Diagnostischer test für menschliches matrix gla- protein und seine verwendung als biomarker
EA202090834A1 (ru) Набор реагентов для выявления маркера эпителиальных карцином
WO2024040238A3 (en) Method of diagnosing and treating prostate cancer using zinc finger protein-like 1 antibodies
CA3240822A1 (en) Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
WO2025010375A3 (en) Anti-grp78 antibodies and their uses
WO2006060188A3 (en) Anti-tenascin monoclonal antibody immunoassays and diagnostic kits